Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411319 · ClinicalTrials.gov registry record · NA
MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
A NA study, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT01411319 is a NA study that has completed, run by University of Miami. The registered enrollment target is 25 participants.
The verdict
NCT01411319, a NA study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The hypotheses of this study are: 1. Delivery of single fraction Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) to the dominant tumor lesion(s) in the prostate as identified by multiparametric functional Magnetic Resonance Imaging is safe and feasible when given prior to standard prostate radiotherapy. 2. Biomarker expression levels differ in the functional MRI identified suspicious tumor regions and unsuspicious tumor regions. The investigators hypothesize that a significant source of variation in biomarker levels is due to tumor heterogeneity and that it is molecular abnormalities in the dominant tumor areas that are angiogenic and determine outcome.
Interventions
- RADIATION Lattice Extreme Ablative Dose Radiation Therapy
- RADIATION Standard IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-12-27 |
| Est. Completion | 2020-03-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411319
The ClinicalTrials.gov registry entry for NCT01411319 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lattice Extreme Ablative Dose Radiation Therapy is the first listed.
NCT01411319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411319 about?
NCT01411319 is a clinical study titled "MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer". The hypotheses of this study are: 1. Delivery of single fraction Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) to the dominant tumor lesion(s) in the prostate as identified by multiparametric functional Magnetic Resonance Imaging is safe and feasible when given prior to standard prostate r...
What is the current status of trial NCT01411319?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2011-12-27. Estimated completion is 2020-03-02.
What interventions are being tested in trial NCT01411319?
The interventions under investigation include: Lattice Extreme Ablative Dose Radiation Therapy (RADIATION), Standard IMRT (RADIATION).
Who is sponsoring clinical trial NCT01411319?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.